In N-MYC-amplified NB tumors, Akt has been found to be hyperactivated [48] and Akt activation has been demonstrated to be strongly involved in etoposide resistance [46, 49–51], as well as being related to the expression of CD133, a marker of staminality associated with the most aggressive cancer phenotype [52]. Here, AKT1 is linked to neuroblastoma.